Product: Osteoprotegerin Antibody
Catalog: DF6824
Description: Rabbit polyclonal antibody to Osteoprotegerin
Application: WB IHC IF/ICC
Reactivity: Human, Mouse, Rat
Prediction: Pig, Bovine, Horse, Sheep, Rabbit, Dog, Chicken
Mol.Wt.: 45~60kDa; 46kD(Calculated).
Uniprot: O00300
RRID: AB_2838784

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors

Product Info

Source:
Rabbit
Application:
WB 1:500-1:2000, IHC 1:50-1:200, IF/ICC 1:100-1:500
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Mouse,Rat
Prediction:
Pig(100%), Bovine(100%), Horse(100%), Sheep(100%), Rabbit(100%), Dog(100%), Chicken(80%)
Clonality:
Polyclonal
Specificity:
Osteoprotegerin Antibody detects endogenous levels of total Osteoprotegerin.
RRID:
AB_2838784
Cite Format: Affinity Biosciences Cat# DF6824, RRID:AB_2838784.
Conjugate:
Unconjugated.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

MGC29565; OCIF; OPG; Osteoclastogenesis inhibitory factor; Osteoprotegerin; PDB5; TNF receptor superfamily member 11b; TNFRSF 11B; TNFRSF11B; TR 1; TR1; TR11B_HUMAN; Tumor necrosis factor receptor superfamily member 11B;

Immunogens

Immunogen:
Uniprot:
Gene(ID):
Expression:
O00300 TR11B_HUMAN:

Highly expressed in adult lung, heart, kidney, liver, spleen, thymus, prostate, ovary, small intestine, thyroid, lymph node, trachea, adrenal gland, testis, and bone marrow. Detected at very low levels in brain, placenta and skeletal muscle. Highly expressed in fetal kidney, liver and lung.

Description:
The protein encoded by this gene is a member of the TNF-receptor superfamily. This protein is an osteoblast-secreted decoy receptor that functions as a negative regulator of bone resorption. This protein specifically binds to its ligand, osteoprotegerin ligand, both of which are key extracellular regulators of osteoclast development. Studies of the mouse counterpart also suggest that this protein and its ligand play a role in lymph-node organogenesis and vascular calcification. Alternatively spliced transcript variants of this gene have been reported, but their full length nature has not been determined. [provided by RefSeq, Jul 2008]
Sequence:
MNNLLCCALVFLDISIKWTTQETFPPKYLHYDEETSHQLLCDKCPPGTYLKQHCTAKWKTVCAPCPDHYYTDSWHTSDECLYCSPVCKELQYVKQECNRTHNRVCECKEGRYLEIEFCLKHRSCPPGFGVVQAGTPERNTVCKRCPDGFFSNETSSKAPCRKHTNCSVFGLLLTQKGNATHDNICSGNSESTQKCGIDVTLCEEAFFRFAVPTKFTPNWLSVLVDNLPGTKVNAESVERIKRQHSSQEQTFQLLKLWKHQNKDQDIVKKIIQDIDLCENSVQRHIGHANLTFEQLRSLMESLPGKKVGAEDIEKTIKACKPSDQILKLLSLWRIKNGDQDTLKGLMHALKHSKTYHFPKTVTQSLKKTIRFLHSFTMYKLYQKLFLEMIGNQVQSVKISCL

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Pig
100
Horse
100
Bovine
100
Sheep
100
Dog
100
Rabbit
100
Chicken
80
Xenopus
70
Zebrafish
64
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

PTMs - O00300 As Substrate

Site PTM Type Enzyme
N178 N-Glycosylation
S246 Phosphorylation
T360 Phosphorylation
T362 Phosphorylation
S364 Phosphorylation

Research Backgrounds

Function:

Acts as decoy receptor for TNFSF11/RANKL and thereby neutralizes its function in osteoclastogenesis. Inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro. Bone homeostasis seems to depend on the local ratio between TNFSF11 and TNFRSF11B. May also play a role in preventing arterial calcification. May act as decoy receptor for TNFSF10/TRAIL and protect against apoptosis. TNFSF10/TRAIL binding blocks the inhibition of osteoclastogenesis.

PTMs:

N-glycosylated. Contains sialic acid residues.

The N-terminus is blocked.

Subcellular Location:

Secreted.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Tissue Specificity:

Highly expressed in adult lung, heart, kidney, liver, spleen, thymus, prostate, ovary, small intestine, thyroid, lymph node, trachea, adrenal gland, testis, and bone marrow. Detected at very low levels in brain, placenta and skeletal muscle. Highly expressed in fetal kidney, liver and lung.

Subunit Structure:

Homodimer. Interacts with TNFSF10 and TNFSF11.

Research Fields

· Environmental Information Processing > Signaling molecules and interaction > Cytokine-cytokine receptor interaction.   (View pathway)

· Organismal Systems > Development > Osteoclast differentiation.   (View pathway)

References

1). IGFBP7 acts as a negative regulator of RANKL-induced osteoclastogenesis and oestrogen deficiency-induced bone loss. CELL PROLIFERATION (PubMed: 31889368) [IF=8.5]

Application: WB    Species: mouse    Sample: MC3T3-E1

Figure S1.| The results of western-blot analysis showed that different concentrations of recombinant IGFBP7 increased the protein expression of OPG in osteoblastic cell line MC3T3-E1, whereas the expression of RANKL was not affected after 3 days’ IGFBP7 treatment. OPG, osteoprotegerin; RANKL, receptor activator of nuclear factor-κB ligand.

2). Osteogenic potential evaluation of biotin combined with magnesium-doped hydroxyapatite sustained-release film. Materials science & engineering-C, Materials for biological applications (PubMed: 35581076) [IF=7.9]

3). Yunvjian decoction attenuates lipopolysaccharide-induced periodontitis by suppressing NFκB/NLRP3/IL-1β pathway. Journal of ethnopharmacology (PubMed: 37802377) [IF=5.4]

4). Neuropeptide Y1 receptor antagonist promotes osteoporosis and microdamage repair and enhances osteogenic differentiation of bone marrow stem cells via cAMP/PKA/CREB pathway. Aging-US (PubMed: 32381754) [IF=5.2]

Application: WB    Species: rat    Sample: bone marrow

Figure 4. |Y1R antagonist treatment promoted bone formation and inhibit bone resorption in OVX rats. (A) The Alizarin Red S (yellow arrow head) and TRAP staining (red arrow head) of bone tissues in groups. (B) Immunohistochemical analysis of bone tissue among groups for MMP9 and RUNX2 (x 400). (C, D) Western blotting results of MMP, RUNX2, Cath-K, OPG and RANKL expression in bone marrow from rat femurs. The data are expressed as the means ± SD (n = 6 in each group). ***P<0.001; ****P<0.0001 vs. SHAM, and #P<0.05; ####P<0.0001 vs. OVX by one-way ANOVA and Tukey’s post hoc test

5). Hexokinase 2‐mediated glycolysis promotes receptor activator of NF‐κB ligand expression in Porphyromonas gingivalis lipopolysaccharide‐treated osteoblasts. JOURNAL OF PERIODONTOLOGY (PubMed: 34585393) [IF=4.3]

6). Role of microRNA-19b-3p on osteoporosis after experimental spinal cord injury in rats. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (PubMed: 33587904) [IF=3.9]

Application: WB    Species: rat    Sample: osteoblasts

Figure 2. MiR-19b-3p inhibits osteoblast differentiation. (A) RT-PCR analysis was used 443 to detect miRNA-19b-3p expression levels in BMSC-derived osteoblasts after 444 miR-19b-3p-overexpressed or knockdown by corresponding lentivirus. (B) ALP activity in 445 BMSC-derived osteoblasts after miRNA-19b-3p overexpression or knockdown by 446 corresponding lentivirus. (C) RT-PCR was used to detect EBF2 mRNA expression levels in BMSC-derived osteoblasts after miRNA-19b-3p overexpression or knockdown by 448 corresponding lentivirus. Western blot assay was used to detect (D and E) EBF2, (F-H) 449 RANKL and OPG protein expression levels in BMSC-derived osteoblasts after 450 miRNA-19b-3p overexpression or knockdown by corresponding lentivirus. (I) The ratio of 451 OPG to RANKL in BMSC-derived osteoblasts after miRNA-19b-3p overexpression or 452 knockdown by corresponding lentivirus (J) Alizarin red staining was used to detect cell 453 mineralization at day 21 after differentiation after miRNA-19b-3p overexpression or 454 knockdown at 100×. Data are analyzed using unpaired Student’s t-tests and presented as the 455 mean ± SD from three independent experiments. * p < 0.05; ** p < 0.01 vs. the indicated 456 group.

7). Nirogacestat suppresses RANKL-Induced osteoclast formation in vitro and attenuates LPS-Induced bone resorption in vivo. EXPERIMENTAL CELL RESEARCH (PubMed: 31211955) [IF=3.7]

Application: IHC    Species: mouse    Sample: BMMs

Fig. 7.| Histological analysis of the inhibitory effect of PF on LPS-induced bone resorption. (A–C) Representative images of HE and TRAP staining, showing the reduced osteolytic legion and TRAP-positive OCs in the PF-treated groups. (D–G) Representative images of IHC staining of RANKL, OPG, OCN and TNF-α. (H) TRAPpositive OCs number. (H) Quantitative analysis of the expression of RANKL, OPG and RANKL/OPG ratio. The data are presented as the mean ± SD (*p < 0.05,**p < 0.01, ***p < 0.001).

8). Rodent incisor and molar dental follicles show distinct characteristics in tooth eruption. ARCHIVES OF ORAL BIOLOGY (PubMed: 33845260) [IF=3.0]

Application: WB    Species: Rat    Sample: Incisor dental follicle (IF) cells and molar dental follicle (MF) cells

Fig. 5. Differential expression patterns of tooth eruption-related genes and proteins between IF cells and MF cells. (A) Non-induced IF cells and MF cells showed different gene expression patterns; Data are mean ± SD of n = 3 replicates, one-way ANOVA, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. (B) Non-induced and induced IF cells and MF cells showed different protein expression patterns. After induction with CLCCM and HERSCM, there were no significant changes of the expression patterns of tooth eruption-related proteins in IF cells and MF cells. (C) The grey value ratios of Western blotting results; Data are mean ± SD of n = 3 replicates, one-way ANOVA followed by Tukey post hoc test, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. (IF1, MF1 represent the cells cultured by α-MEM; IF2, MF2 represent the cells cultured by α-MEM + CLCCM; IF3, MF3 represent the cells cultured by α-MEM+HERSCM).

9). Low frequency pulsed electromagnetic fields exposure alleviate the abnormal subchondral bone remodeling at the early stage of temporomandibular joint osteoarthritis. BMC Musculoskeletal Disorders (PubMed: 36384557) [IF=2.3]

10). Deletion of osteopontin in non-small cell lung cancer cells affects bone metabolism by regulating miR-34c/Notch1 axis: a clue to bone metastasis. European Journal of Histochemistry (PubMed: 37491944) [IF=2.0]

Application: WB    Species: Human    Sample: SaOS-2 cells

Figure 4.Deletion of osteopontin (OPN) promoted the differentiation and mineralization of osteoblasts. A) Osteocalcin-positive rate of SaOS-2 cells was detected by flow cytometry. B) The expression of osteocalcin in SaOS-2 cells was observed by immunofluorescence staining, and the fluorescence intensity was exhibited on the right. C) Alizarin Red S staining was performed on SaOS-2 cells to evaluate the mineralization. D) The protein expression of RANKL, M-CSF and OPG was detected by Western blot.

Load more

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.